| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Virology [I. Y., G. K.], Immunology [M. M., K. N.], Medical Institute of Bioregulation, and Department of Surgery II, Faculty of Medicine, [T. I., K. S.], Kyushu University Fukuoka 812; and Department of Chest Surgery, National Kyushu Cancer Center, Fukuoka 815 [T. Y.], Japan
The purpose of this study was to elucidate a possible immune response to tumor cells mediated by tumor-infiltrating lymphocytes (TIL) in lung cancer. In flow cytometry, the majority of T-cells of TIL were CD45RA, CD45RO+, and CDw29high, and expressed HLA-DR. The expression of interleukin 2 receptor ß chain increased in both CD4+ and CD8+ TIL compared with both types of T-cells in peripheral blood. These results indicate that the major population of TIL is activated memory T-cells. The TIL preparation, which was usually contaminated with 5 to 10% tumor cells, did not exhibit any response in autologous mixed lymphocyte-tumor culture even in the presence of interleukin 2 (IL-2) in all five cases tested. Although purified T-cells from TIL showed the positive response in only 1 of 10 cases tested without addition of IL-2, it occurred in 7 of 10 cases in the addition of a low concentration of IL-2. The IL-2-dependent response to irradiated autologous tumor cells was suppressed when nonirradiated autologous tumor cells were added to the culture. Culture supernatants of four lung cancer cell lines and freshly prepared lung cancer cells obtained from 6 cases exhibited suppressive activity against anti-CD3 antibody-induced mitogenesis of peripheral blood mononuclear cells from healthy donors. We suggest that, taken together, (a) the major population of TIL in lung cancer are activated memory T-cells, and they include tumor-reactive ones, and that (b) the function of the TIL is impaired by unavailability of IL-2 and/or by suppression due to lung cancer cell-derived factor(s).
1 Supported in part by Grant 02557049 from Ministry of Education, Science and Culture, and a Grant-in-Aid for Cancer Research from Ministry of Health and Welfare, Japan.
2 To whom requests for reprints should be addressed, at Department of Virology, Medical Institute of Bioregulation, Kyushu University 69, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812, Japan.
Received 7/12/91. Accepted 11/20/91.
This article has been cited by other articles:
![]() |
S.-C. Yang, R. K. Batra, S. Hillinger, K. L. Reckamp, R. M. Strieter, S. M. Dubinett, and S. Sharma Intrapulmonary Administration of CCL21 Gene-Modified Dendritic Cells Reduces Tumor Burden in Spontaneous Murine Bronchoalveolar Cell Carcinoma. Cancer Res., March 15, 2006; 66(6): 3205 - 3213. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sharma, L. Zhu, S. C. Yang, L. Zhang, J. Lin, S. Hillinger, B. Gardner, K. Reckamp, R. M. Strieter, M. Huang, et al. Cyclooxygenase 2 Inhibition Promotes IFN-{gamma}-Dependent Enhancement of Antitumor Responses J. Immunol., July 15, 2005; 175(2): 813 - 819. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sharma, S.-C. Yang, L. Zhu, K. Reckamp, B. Gardner, F. Baratelli, M. Huang, R. K. Batra, and S. M. Dubinett Tumor Cyclooxygenase-2/Prostaglandin E2-Dependent Promotion of FOXP3 Expression and CD4+CD25+ T Regulatory Cell Activities in Lung Cancer Cancer Res., June 15, 2005; 65(12): 5211 - 5220. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Batra, Y. Lin, S. Sharma, M. Dohadwala, J. Luo, M. Pold, and S. M. Dubinett Non-Small Cell Lung Cancer-derived Soluble Mediators Enhance Apoptosis in Activated T Lymphocytes through an I{kappa}B Kinase-dependent Mechanism Cancer Res., February 1, 2003; 63(3): 642 - 646. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. D. Hess, N. K. Egilmez, N. Bailey, T. M. Anderson, E. Mathiowitz, S. H. Bernstein, and R. B. Bankert Human CD4+ T Cells Present Within the Microenvironment of Human Lung Tumors Are Mobilized by the Local and Sustained Release of IL-12 to Kill Tumors In Situ by Indirect Effects of IFN-{gamma} J. Immunol., January 1, 2003; 170(1): 400 - 412. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yasuda, M. Takenoyama, Y. Obata, M. Sugaya, T. So, T. Hanagiri, K. Sugio, and K. Yasumoto Tumor-infiltrating B Lymphocytes as a Potential Source of Identifying Tumor Antigen in Human Lung Cancer Cancer Res., March 1, 2002; 62(6): 1751 - 1756. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. G. S. Buggins, D. Milojkovic, M. J. Arno, N. C. Lea, G. J. Mufti, N. S. B. Thomas, and W. J. R. Hirst Microenvironment Produced by Acute Myeloid Leukemia Cells Prevents T Cell Activation and Proliferation by Inhibition of NF-{kappa}B, c-Myc, and pRb Pathways J. Immunol., November 15, 2001; 167(10): 6021 - 6030. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Yasuda, Y. Tanaka, K. Fujii, and K. Yasumoto CD44 stimulation down-regulates Fas expression and Fas-mediated apoptosis of lung cancer cells Int. Immunol., October 1, 2001; 13(10): 1309 - 1319. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Christ, S. Matzku, C. Burger, and M. Zöller Interleukin 2-Antibody and Tumor Necrosis Factor-Antibody Fusion Proteins Induce Different Antitumor Immune Responses in Vivo Clin. Cancer Res., May 1, 2001; 7(5): 1385 - 1397. [Abstract] [Full Text] |
||||
![]() |
O. Christ, S. Seiter, S. Matzku, C. Burger, and M. Zöller Efficacy of Local versus Systemic Application of Antibody-Cytokine Fusion Proteins in Tumor Therapy Clin. Cancer Res., April 1, 2001; 7(4): 985 - 998. [Abstract] [Full Text] |
||||
![]() |
S. M. Dubinett, R. K. Batra, P. W. Miller, and S. Sharma Tumor Antigens in Thoracic Malignancy Am. J. Respir. Cell Mol. Biol., May 1, 2000; 22(5): 524 - 527. [Full Text] |
||||
![]() |
M. Stolina, S. Sharma, Y. Lin, M. Dohadwala, B. Gardner, J. Luo, L. Zhu, M. Kronenberg, P. W. Miller, J. Portanova, et al. Specific Inhibition of Cyclooxygenase 2 Restores Antitumor Reactivity by Altering the Balance of IL-10 and IL-12 Synthesis J. Immunol., January 1, 2000; 164(1): 361 - 370. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Maccalli, P. Pisarra, C. Vegetti, M. Sensi, G. Parmiani, and A. Anichini Differential Loss of T Cell Signaling Molecules in Metastatic Melanoma Patients' T Lymphocyte Subsets Expressing Distinct TCR Variable Regions J. Immunol., December 15, 1999; 163(12): 6912 - 6923. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Sharma, M. Stolina, Y. Lin, B. Gardner, P. W. Miller, M. Kronenberg, and S. M. Dubinett T Cell-Derived IL-10 Promotes Lung Cancer Growth by Suppressing Both T Cell and APC Function J. Immunol., November 1, 1999; 163(9): 5020 - 5028. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Uzzo, P. Rayman, V. Kolenko, P. E. Clark, T. Bloom, A. M. Ward, L. Molto, C. Tannenbaum, L. J. Worford, R. Bukowski, et al. Mechanisms of Apoptosis in T Cells from Patients with Renal Cell Carcinoma Clin. Cancer Res., May 1, 1999; 5(5): 1219 - 1229. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Ling, P. Rayman, R. Uzzo, P. Clark, H. J. Kim, R. Tubbs, A. Novick, R. Bukowski, T. Hamilton, and J. Finke Impaired Activation of NFkappa B in T Cells From a Subset of Renal Cell Carcinoma Patients Is Mediated by Inhibition of Phosphorylation and Degradation of the Inhibitor, Ikappa Balpha Blood, August 15, 1998; 92(4): 1334 - 1341. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |